Statistically significant lower risk is seen for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance. All remain significant for higher quality studies. 64 studies from 58 independent teams in 27 different countries show significant improvements.
Meta analysis using the most serious outcome shows 61% [50‑69%] and 85% [77‑90%] lower risk for early treatment and prophylaxis, with similar results for higher quality studies,
primary outcomes, peer-reviewed studies, and for RCTs.
Results are very robust — in worst case exclusion sensitivity analysis 63 of 105 studies must be excluded to avoid finding statistically significant efficacy.
No treatment or intervention is 100% effective. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, which may be significantly more effective. Pharmacokinetics show significant inter-individual variability1. Efficacy may vary depending on the manufacturer2.
Over 20 countries adopted ivermectin for COVID-19. The evidence base is much larger and has much lower conflict of interest than typically used to approve drugs.
All data to reproduce this paper and sources are in the appendix. Multiple other meta analyses show efficacy3-7.
7 meta analyses show significant improvements with ivermectin for mortality
1-6,
hospitalization
7,
recovery
3, and
cases
3.